A homespun elixir

摘要

As a country with an ageing and wealthy population, Japan ought to have a thriving drug market. In fact, the market is ailing. Hefty regulations and price controls mean that many new drugs appear elsewhere before they make it to Japan, if ever. The Japanese also spend rather less on their health care than most rich countries-around 8% of GDP-particular-ly profligate America.